{"id":43583,"date":"2025-10-16T16:18:37","date_gmt":"2025-10-16T08:18:37","guid":{"rendered":"https:\/\/flcube.com\/?p=43583"},"modified":"2025-10-16T16:18:38","modified_gmt":"2025-10-16T08:18:38","slug":"help-therapeutics-secures-nmpa-approval-for-hicm388-chinas-first-cell%e2%80%91based-therapy-for-stemi","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43583","title":{"rendered":"HELP\u202fTherapeutics Secures NMPA Approval for HiCM388, China\u2019s First Cell\u2011Based Therapy for STEMI"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>HELP Therapeutics Corp.<\/strong>, a pioneer in cell\u2011based therapeutics, announced that the National Medical Products Administration (NMPA) has formally approved its Investigational New Drug (IND) application for <strong>Human Umbilical Cord Mesenchymal Stem Cells for Injection (HiCM388)<\/strong> (Acceptance Number:\u202fCXSL2500607). The Class\u202f1 drug targets patients who have undergone revascularization following an acute ST\u2011segment elevation myocardial infarction (STEMI) and represents the first cell\u2011based innovative product in China for this indication.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-highlights\">Key Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NMPA Approval<\/strong> \u2013 IND for HiCM388 cleared for clinical testing in China.<\/li>\n\n\n\n<li><strong>Target Indication<\/strong> \u2013 Post\u2011revascularization care for acute STEMI patients.<\/li>\n\n\n\n<li><strong>First\u2011Mover Status<\/strong> \u2013 China\u2019s inaugural cell\u2011based therapy for myocardial infarction.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-help-therapeutics-track-record\">HELP\u202fTherapeutics\u2019 Track Record<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Global First<\/strong><\/td><td>iPSC\u2011derived cardiomyocyte therapy for severe heart failure received dual IND approval in China and the U.S., launching multi\u2011center trials in China, the U.S., Singapore, and Thailand.<\/td><\/tr><tr><td><strong>R&amp;D Focus<\/strong><\/td><td>Long\u2011standing commitment to innovative cell\u2011based drugs for unmet clinical needs.<\/td><\/tr><tr><td><strong>Portfolio Expansion<\/strong><\/td><td>HiCM388 adds a new therapeutic modality to the company\u2019s pipeline of regenerative medicines.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-path\">Clinical Development Path<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Phase\u202fI\/II<\/strong> \u2013 Initial safety and dose\u2011finding studies in STEMI patients with prior revascularization.<\/li>\n\n\n\n<li><strong>Phase\u202fIIb\/III<\/strong> \u2013 Efficacy evaluation on cardiac function, infarct size reduction, and long\u2011term outcomes.<\/li>\n\n\n\n<li><strong>Regulatory Strategy<\/strong> \u2013 Parallel submissions to the U.S. FDA and EU EMA to accelerate global access.<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>HELP Therapeutics Corp., a pioneer in cell\u2011based therapeutics, announced that the National Medical Products Administration&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43586,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[77,62,1595],"class_list":["post-43583","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cell-therapy","tag-clinical-trial-approval-initiation","tag-help-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HELP\u202fTherapeutics Secures NMPA Approval for HiCM388, China\u2019s First Cell\u2011Based Therapy for STEMI - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"HELP Therapeutics Corp., a pioneer in cell\u2011based therapeutics, announced that the National Medical Products Administration (NMPA) has formally approved its Investigational New Drug (IND) application for Human Umbilical Cord Mesenchymal Stem Cells for Injection (HiCM388) (Acceptance Number:\u202fCXSL2500607). The Class\u202f1 drug targets patients who have undergone revascularization following an acute ST\u2011segment elevation myocardial infarction (STEMI) and represents the first cell\u2011based innovative product in China for this indication.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43583\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HELP\u202fTherapeutics Secures NMPA Approval for HiCM388, China\u2019s First Cell\u2011Based Therapy for STEMI\" \/>\n<meta property=\"og:description\" content=\"HELP Therapeutics Corp., a pioneer in cell\u2011based therapeutics, announced that the National Medical Products Administration (NMPA) has formally approved its Investigational New Drug (IND) application for Human Umbilical Cord Mesenchymal Stem Cells for Injection (HiCM388) (Acceptance Number:\u202fCXSL2500607). The Class\u202f1 drug targets patients who have undergone revascularization following an acute ST\u2011segment elevation myocardial infarction (STEMI) and represents the first cell\u2011based innovative product in China for this indication.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43583\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-16T08:18:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-16T08:18:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1604.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43583#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43583\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HELP\u202fTherapeutics Secures NMPA Approval for HiCM388, China\u2019s First Cell\u2011Based Therapy for STEMI\",\"datePublished\":\"2025-10-16T08:18:37+00:00\",\"dateModified\":\"2025-10-16T08:18:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43583\"},\"wordCount\":261,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43583#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1604.webp\",\"keywords\":[\"Cell-therapy\",\"Clinical trial approval \\\/ initiation\",\"HELP Therapeutics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43583#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43583\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43583\",\"name\":\"HELP\u202fTherapeutics Secures NMPA Approval for HiCM388, China\u2019s First Cell\u2011Based Therapy for STEMI - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43583#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43583#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1604.webp\",\"datePublished\":\"2025-10-16T08:18:37+00:00\",\"dateModified\":\"2025-10-16T08:18:38+00:00\",\"description\":\"HELP Therapeutics Corp., a pioneer in cell\u2011based therapeutics, announced that the National Medical Products Administration (NMPA) has formally approved its Investigational New Drug (IND) application for Human Umbilical Cord Mesenchymal Stem Cells for Injection (HiCM388) (Acceptance Number:\u202fCXSL2500607). The Class\u202f1 drug targets patients who have undergone revascularization following an acute ST\u2011segment elevation myocardial infarction (STEMI) and represents the first cell\u2011based innovative product in China for this indication.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43583#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43583\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43583#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1604.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1604.webp\",\"width\":1080,\"height\":608,\"caption\":\"HELP\u202fTherapeutics Secures NMPA Approval for HiCM388, China\u2019s First Cell\u2011Based Therapy for STEMI\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43583#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HELP\u202fTherapeutics Secures NMPA Approval for HiCM388, China\u2019s First Cell\u2011Based Therapy for STEMI\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HELP\u202fTherapeutics Secures NMPA Approval for HiCM388, China\u2019s First Cell\u2011Based Therapy for STEMI - Insight, China&#039;s Pharmaceutical Industry","description":"HELP Therapeutics Corp., a pioneer in cell\u2011based therapeutics, announced that the National Medical Products Administration (NMPA) has formally approved its Investigational New Drug (IND) application for Human Umbilical Cord Mesenchymal Stem Cells for Injection (HiCM388) (Acceptance Number:\u202fCXSL2500607). The Class\u202f1 drug targets patients who have undergone revascularization following an acute ST\u2011segment elevation myocardial infarction (STEMI) and represents the first cell\u2011based innovative product in China for this indication.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43583","og_locale":"en_US","og_type":"article","og_title":"HELP\u202fTherapeutics Secures NMPA Approval for HiCM388, China\u2019s First Cell\u2011Based Therapy for STEMI","og_description":"HELP Therapeutics Corp., a pioneer in cell\u2011based therapeutics, announced that the National Medical Products Administration (NMPA) has formally approved its Investigational New Drug (IND) application for Human Umbilical Cord Mesenchymal Stem Cells for Injection (HiCM388) (Acceptance Number:\u202fCXSL2500607). The Class\u202f1 drug targets patients who have undergone revascularization following an acute ST\u2011segment elevation myocardial infarction (STEMI) and represents the first cell\u2011based innovative product in China for this indication.","og_url":"https:\/\/flcube.com\/?p=43583","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-16T08:18:37+00:00","article_modified_time":"2025-10-16T08:18:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1604.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43583#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43583"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HELP\u202fTherapeutics Secures NMPA Approval for HiCM388, China\u2019s First Cell\u2011Based Therapy for STEMI","datePublished":"2025-10-16T08:18:37+00:00","dateModified":"2025-10-16T08:18:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43583"},"wordCount":261,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43583#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1604.webp","keywords":["Cell-therapy","Clinical trial approval \/ initiation","HELP Therapeutics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43583#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43583","url":"https:\/\/flcube.com\/?p=43583","name":"HELP\u202fTherapeutics Secures NMPA Approval for HiCM388, China\u2019s First Cell\u2011Based Therapy for STEMI - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43583#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43583#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1604.webp","datePublished":"2025-10-16T08:18:37+00:00","dateModified":"2025-10-16T08:18:38+00:00","description":"HELP Therapeutics Corp., a pioneer in cell\u2011based therapeutics, announced that the National Medical Products Administration (NMPA) has formally approved its Investigational New Drug (IND) application for Human Umbilical Cord Mesenchymal Stem Cells for Injection (HiCM388) (Acceptance Number:\u202fCXSL2500607). The Class\u202f1 drug targets patients who have undergone revascularization following an acute ST\u2011segment elevation myocardial infarction (STEMI) and represents the first cell\u2011based innovative product in China for this indication.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43583#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43583"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43583#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1604.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1604.webp","width":1080,"height":608,"caption":"HELP\u202fTherapeutics Secures NMPA Approval for HiCM388, China\u2019s First Cell\u2011Based Therapy for STEMI"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43583#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HELP\u202fTherapeutics Secures NMPA Approval for HiCM388, China\u2019s First Cell\u2011Based Therapy for STEMI"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1604.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43583","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43583"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43583\/revisions"}],"predecessor-version":[{"id":43587,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43583\/revisions\/43587"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43586"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43583"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43583"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43583"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}